Integer Holdings Corp ITGR

Healthcare SIC 3845 - Electromedical & Electrotherapeutic Apparatus NAICS Manufacturing › Computer and Electronic Product Manufacturing › Navigational, Measuring, Electromedical, and Control Instruments Manufacturing derived NYSE

Integer Holdings Corporation, headquartered in Plano, Texas, is one of the world's largest medical device contract development and manufacturing organizations ("CDMOs"), serving the Cardio and Vascular, Neuromodulation, and Cardiac Rhythm Management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. Our brands include Greatbatch Medical® and Lake Region Medical®. Our primary customers include large, multi-national original equipment manufacturers ("OEMs") and their affiliated subsidiaries. When used in this report, the terms "Integer," "we," "us," "our" and the "Company" mean Integer Holdings Corporation and its subsidiaries.

Last close 126.54 2026-10-23
Market cap $4.30B 2026-07-03 share count
52-week range 62.00 - 126.83

Valuation FY2025 figures against the last close

P/S2.3x
P/E43.8x
P/FCF40.9x
EV/EBITDA15.5x
Dividend yield—
Diluted EPS2.89

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • U.S.
  • Rest of world
  • Costa Rica
  • Puerto Rico
  • Ireland
Revenue by geography, 5 categories over 3 years. The same figures are in the table below. FY2025 U.S., FY2025: 979.8M (52.9%) 53% U.S. Rest of world, FY2025: 469.9M (25.3%) 25% Rest of world Costa Rica, FY2025: 173.5M (9.4%) 9% Costa Rica Puerto Rico, FY2025: 131.3M (7.1%) 7% Ireland, FY2025: 99.2M (5.3%) 5% Ireland FY2024 U.S., FY2024: 938.7M (54.7%) 55% Rest of world, FY2024: 431.8M (25.2%) 25% Costa Rica, FY2024: 124.7M (7.3%) 7% Puerto Rico, FY2024: 137.1M (8.0%) 8% Ireland, FY2024: 84.4M (4.9%) 5% FY2023 U.S., FY2023: 872.9M (56.1%) 56% Rest of world, FY2023: 383.7M (24.7%) 25% Costa Rica, FY2023: 108.4M (7.0%) 7% Puerto Rico, FY2023: 121.5M (7.8%) 8% Ireland, FY2023: 69.1M (4.4%) 4%
Region FY2025FY2024FY2023
U.S. $979.8M $938.7M $872.9M
Rest of world $469.9M $431.8M $383.7M
Costa Rica $173.5M $124.7M $108.4M
Puerto Rico $131.3M $137.1M $121.5M
Ireland $99.2M $84.4M $69.1M

As the company reported it, from the “SEGMENT AND GEOGRAPHIC INFORMATION (Sales by Geographic Information) (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $1.85B$1.72B$1.56B$1.33B$1.22B$1.07B$1.26B$1.22B$1.14B$1.08B
Cost of revenue $1.35B$1.26B$1.15B$985.5M$884.1M$787.7M$903.1M$852.3M$782.1M$737.8M
Gross profit $500.4M$459.0M$409.9M$345.8M$337.0M$285.7M$355.0M$362.7M$354.0M$337.7M
SG&A $211.7M$185.2M$173.2M$158.1M$141.4M$109.0M$138.7M$142.4M$143.1M$136.4M
Total operating expenses $279.1M$250.8M$246.6M$233.1M$201.3M$165.1M$197.4M$207.1M$228.4M$244.8M
Operating income $221.3M$208.2M$163.3M$112.7M$135.7M$120.6M$157.6M$155.6M$125.6M$92.9M
Interest expense $43.2M$56.4M$51.3M$37.3M$31.6M$38.2M$52.5M$99.3M$64.0M$68.3M
Pre-tax income $125.4M$147.6M$105.4M$68.7M$101.1M$86.2M$105.2M$61.1M$49.3M$28.2M
Income tax $22.6M$26.5M$16.2M$8.9M$8.0M$8.9M$14.0M$14.1M$37.8M$3.3M
Net income $102.8M$119.9M$90.7M$66.4M$96.8M$77.3M$96.3M$168.0M$66.7M$6.0M
EPS, basic 2.963.572.722.002.932.352.955.232.120.19
EPS, diluted 2.893.362.691.992.912.332.925.152.080.19
Shares, diluted (wtd. avg.) 35.6M35.6M33.8M33.4M33.3M33.1M33.0M32.6M32.1M31.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $17.2M$46.5M$23.7M$24.3M$17.9M$49.2M$13.5M$25.6M$44.1M$52.1M
Receivables $346.1M$245.3M$231.3M$224.3M$182.3M$156.2M$192.0M$185.5M$194.8M$204.6M
Inventory $253.7M$247.1M$229.1M$208.8M$155.7M$149.3M$167.3M$190.1M$176.7M$225.2M
Total current assets $770.1M$671.1M$617.7M$558.3M$453.0M$412.9M$415.4M$416.2M$531.9M$517.3M
Property, plant and equipment $536.4M$465.8M$392.6M$317.2M$277.1M$254.0M$246.2M$231.3M$235.2M$372.0M
Goodwill $1.11B$1.02B$994.0M$965.2M$924.7M$859.4M$839.6M$832.3M$839.9M$967.3M
Other intangibles $825.4M$778.3M$779.6M$819.9M$807.8M$757.2M$775.8M$812.3M$862.9M$940.1M
Total assets $3.41B$3.08B$2.94B$2.79B$2.58B$2.37B$2.35B$2.33B$2.85B$2.83B
Accounts payable $113.1M$101.5M$118.3M$110.8M$76.9M$51.6M$65.0M$57.2M$64.6M$77.9M
Short-term debt $0$10.0M$0$18.2M$15.2M$37.5M$37.5M$37.5M$30.5M$31.3M
Total current liabilities $232.0M$227.2M$221.0M$223.8M$159.6M$156.2M$179.1M$164.6M$209.0M$185.2M
Long-term debt $1.19B$980.2M$959.9M$907.1M$812.9M$693.8M$777.3M$888.0M$1.58B$1.70B
Total liabilities $1.66B$1.46B$1.42B$1.38B$1.23B$1.10B$1.20B$1.27B$1.95B$2.11B
Retained earnings $994.1M$891.2M$771.4M$680.7M$614.3M$517.5M$440.3M$344.5M$176.1M$109.1M
Total equity $1.75B$1.62B$1.52B$1.42B$1.35B$1.27B$1.15B$1.06B$893.4M$725.2M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $196.1M$205.2M$180.2M$116.4M$156.7M$181.3M$165.4M$167.3M$149.4M$105.5M
Depreciation and amortisation $130.7M$111.0M$98.8M$92.0M$81.4M$79.3M$77.9M$89.0M$102.8M$90.5M
Stock-based compensation $23.2M$24.8M$23.3M$21.0M$16.2M$9.2M$9.3M$10.5M$14.7M$8.4M
Capital expenditure $91.0M$105.4M$119.9M$74.7M$53.5M$46.8M$48.2M$44.9M$47.3M$58.6M
Investing cash flow -$270.7M-$195.4M-$163.4M-$200.4M-$271.0M-$56.6M-$58.9M$536.7M-$47.9M-$63.3M
Financing cash flow $43.6M$13.3M-$18.0M$92.5M$82.0M-$88.6M-$117.9M-$725.1M-$111.7M-$72.1M
Buybacks $50.0M$0$0———————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001114483-26-000009.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 500M 1B 1.5B 2B Revenue, FY2016: 1.1B Gross profit, FY2016: 337.7M Net income, FY2016: 6M Revenue, FY2017: 1.1B Gross profit, FY2017: 354M Net income, FY2017: 66.7M Revenue, FY2018: 1.2B Gross profit, FY2018: 362.7M Net income, FY2018: 168M Revenue, FY2019: 1.3B Gross profit, FY2019: 355M Net income, FY2019: 96.3M Revenue, FY2020: 1.1B Gross profit, FY2020: 285.7M Net income, FY2020: 77.3M Revenue, FY2021: 1.2B Gross profit, FY2021: 337M Net income, FY2021: 96.8M Revenue, FY2022: 1.3B Gross profit, FY2022: 345.8M Net income, FY2022: 66.4M Revenue, FY2023: 1.6B Gross profit, FY2023: 409.9M Net income, FY2023: 90.7M Revenue, FY2024: 1.7B Gross profit, FY2024: 459M Net income, FY2024: 119.9M Revenue, FY2025: 1.9B Gross profit, FY2025: 500.4M Net income, FY2025: 102.8M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $1.08B $1.14B $1.22B $1.26B $1.07B $1.22B $1.33B $1.56B $1.72B $1.85B
Gross profit $337.7M $354.0M $362.7M $355.0M $285.7M $337.0M $345.8M $409.9M $459.0M $500.4M
Net income $6.0M $66.7M $168.0M $96.3M $77.3M $96.8M $66.4M $90.7M $119.9M $102.8M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Material agreement signed Item 1.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3845

TickerCompanyMarket capP/ERevenue growth
MDT Medtronic plc $122.04B 25.6x 8.4%
LIVN LivaNova PLC $4.46B — 10.7%
TMDX TransMedics Group, Inc. $2.45B 14.5x 37.1%
AXGN Axogen, Inc. $2.05B — 20.2%
BLFS BIOLIFE SOLUTIONS INC $1.89B — 28.9%
CNMD CONMED Corp $1.48B 32.6x 5.2%
CBLL Ceribell, Inc. $1.04B — 36.1%
CV CapsoVision, Inc $349.8M — 15.3%